Tracer study definition

Tracer study means a field study conducted to determine the disinfectant contact time, T, provided by a water system component, such as a clearwell or storage reservoir, used for Giardia lamblia cyst and virus inactivation. The study involves introducing a tracer chemical at the inlet of the contact basin and measuring the resulting outlet tracer concentration as a function of time.
Sample 1Sample 2Sample 3
Tracer study means a test conducted using a tracer to measure the flow velocity, hydraulic conductivity, flow direction, hydrodynamic dispersion, partitioning coefficient, or other property of a hydrologic system.
Sample 1Sample 2Sample 3
Tracer study means a due diligence study that is conducted to ensure proper procedures according to World Bank OP 4.12 have been carried out and that outcomes are what would have been expected under this policy framework in the event that land acquisition and/or resettlement has occurred in an area of a sub- Project before the appraisal date.
Sample 1Sample 2

Examples of Tracer study in a sentence

  • Fate of nitrogen in riparian forest soils and trees: an 15N Tracer study simulating salmon decay.

  • Tracer study on the distribution of iron from Spirulina (Arthospira platensis) in vivo.

  • Tracer study is simply about locating the where about, functionality of a particular aspect.

  • Tracer study for the graduates from public VET schools in Albania in 2017, Tirana.

  • Cruz-Soriano, Tracer study on Filipino domestic workers abroad (Geneva, International Organization for Migration, 1995), p.30.

  • After acceptance of the Draft Tracer study & Employability outcomes Report by MPSSDEGB, the Agency has to submit the final descriptive report within 10 days for the date of acceptance.

  • Tracer study, by design, acknowledges that targeted participants may not be traceable because of a range of reasons, which include relocation (migration), death, and loss or change of contact details (Ramrathan, 1997).

  • The Tracer study should ideally be conducted between 6-12 months after graduation from the cohort, depending on logistical feasibility.

  • Task DescriptionYear 1Year 2Year 3Year 4Year 5Year 6Primary investigations Permitting CEQA Design Bidding Construction Tracer study and analysis Figure 9-6.

  • ApproachFollowing are the milestones or steps adopted in conducting the Tracer study: 1.


More Definitions of Tracer study

Tracer study means a field study con- ducted to determine the disinfectant contact time, T, provided
Sample 1
Tracer study means a due diligence study conducted to ensure proper procedures according to World Bank OP 4.12 have been carried out and the outcomes have been what would have been expected under this policy framework in the event land acquisition and/or resettlement has occurred in an area of a subproject before the appraisal date.
Sample 1
Tracer study means a test conducted using a tracer to measure the flow velocity, hydraulic conductivity, flow direc- tion, hydrodynamic dispersion, partitioning coefficient, or other property of a hydrologic system.
Sample 1

Related to Tracer study

  • Clinical Study means a Phase I Study, Phase II Study, Phase III Study, as applicable.

  • Clinical Trial means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-approval human clinical trial, as applicable.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • Phase 3 Study means a clinical study of an investigational product in patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Marketing Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States. The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents and a Phase 3 Study shall be deemed commenced when Initiated.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.